Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma
Disease Markers · 17.08.2022 · 2022 · 1-6
DOI: 10.1155/2022/4506350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Markers, erschienen am 17.08.2022. Verfasst von Zhaoxin Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Qilu Hospital of Shandong University, Jinan, 250012 Shandong, China. Hauptthemen laut MEDLINE: Carcinoma, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R & D Plan of Shandong Province.
Abstract (Originalsprache)
Objective
To investigate the effect of bicalutamide combined with docetaxel on the levels of prostate-specific antigen (PSA) in serum and vascular endothelial growth factor (VEGF) in patients with advanced prostate carcinoma (PCa).
Methods
The clinical data of 103 patients with advanced PCa at our hospital between Feb. 2020 and Feb. 2021 were retrospectively analyzed, the 90 of whom screened by inclusion and exclusion criteria were finally chosen as research objects. They were divided into a control group and an experimental group according to the order of admission, with 45 cases in each group. The control group was treated with conventional treatment, while the experimental group underwent the combination of bicalutamide and docetaxel, and the clinical indices of the two groups were compared.
Results
After treatment, the serum indices in the experimental group were remarkably lower than those in the control group ( P < 0.001 ), with remarkably lower incidence of toxic and side effects ( P < 0.05 ) and higher Expanded Prostate Cancer Index Composite (EPIC) scores ( P < 0.001 ) in the experimental group than in the control group.
Conclusion
The implementation of bicalutamide combined with docetaxel in patients with advanced PCa is effective in reducing the inflammatory expression and improving quality of life and has a higher safety profile. Compared with conventional treatment, this method is of high application value, and further studies will help establish a better solution for such patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Qilu Hospital of Shandong University, Jinan, 250012 Shandong, China.
- Department of Endocrinology, Jinan Central Hospital, Jinan, 250033 Shandong, China.
- Department of Urology, Jinan Seventh People's Hospital, Jinan, 251400 Shandong, China.
ORCID-Profile: Lei Yan
Förderung
- Key R & D Plan of Shandong Province
Zitieren
APA
Guo, Z., Hu, X., Lv, R., Zhang, Y., Meng, L., Liu, Z., & Yan, L. (2022). Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma. Disease Markers, 2022, 1-6. https://doi.org/10.1155/2022/4506350
Vancouver
Guo Z, Hu X, Lv R, Zhang Y, Meng L, Liu Z, et al. Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma. Disease Markers. 2022;2022:1-6. doi:10.1155/2022/4506350
BibTeX
@article{Guo2022,
author = {Guo, Zhaoxin and Hu, Xiaolin and Lv, Renguang and Zhang, Yongzhen and Meng, Liwei and Liu, Zhaoxu and Yan, Lei},
title = {Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma},
journal = {Disease Markers},
year = {2022},
volume = {2022},
pages = {1--6},
doi = {10.1155/2022/4506350}
}
EUVIMED